Psilocybin for Depression: Why One Dose May Change the Brain

For decades, people struggling with major depression have been told they may need antidepressants every day for years, perhaps indefinitely. While some patients may get very good results, many people report only partial relief. Others stop treatment because of side effects ranging from emotional blunting and sexual problems to weight gain and difficult withdrawal symptoms. Now, researchers are exploring a radically different approach. Instead of chronic daily treatment, studies suggest that psilocybin for depression may produce rapid and surprisingly durable benefits after just one carefully supervised psychedelic session. Even more intriguing, scientists are beginning to uncover evidence that a single dose may temporarily reorganize brain networks linked to rigid thinking, rumination and emotional distress. Another compound, DMT (dimethyltryptamine), may also produce long-lasting antidepressant benefits. 

One Dose of Psilocybin for Depression Changes Brain Activity

An intriguing new study published in Nature Communications (April 6, 2026) found that a single dose of psilocybin produced measurable changes in brain structure and connectivity that persisted for at least a month. Researchers reported increases in “brain flexibility,” along with improvements in psychological insight and well-being.

Here is how the authors describe why they undertook this research:

“Psychedelic drugs are re-emerging as promising scientific and clinical tools. However, despite a rapidly expanding literature on their therapeutic value, the neural mechanisms underlying psychedelic effects remain unclear.

“This study provides the most comprehensive synthesis of psychedelic brain action to date, helping resolve inconsistencies and offering a probabilistic map of how psychedelics alter large-scale brain organization. We hereby provide a cornerstone to benchmark and shepherd future psychedelic neuroimaging research.”

What they did:

The Result of This Analysis:

Recent brain-imaging studies suggest psilocybin temporarily disrupts rigid communication patterns in the brain’s ‘default mode network,’ a system associated with repetitive self-focused thinking and depressive rumination. Scientists believe this temporary ‘reset’ may help some people escape deeply entrenched negative thought loops.

Scientists from Imperial College London and the University of California San Francisco used EEG recordings and advanced MRI scans to study healthy volunteers before and after psilocybin exposure. Within an hour, researchers detected increased ‘entropy’ in the brain, meaning brain activity became more flexible, diverse and less rigidly organized. A month later, specialized scans suggested some neural pathways appeared denser and more interconnected.

Professor Robin Carhart-Harris, one of the leading researchers in psychedelic science, described the findings as remarkable because measurable anatomical brain changes were still visible a month after a single psychedelic experience.

This does not mean psilocybin “grows new brains.” But it does support the idea that psychedelics may temporarily increase neuroplasticity, allowing the brain to become less stuck in repetitive patterns.

Psilocybin for Depression Versus Traditional Antidepressants

Standard antidepressants such as SSRIs often take weeks to begin working. Even then, many patients experience only modest improvement. Psilocybin appears to work differently.

A previous study published in Nature Medicine (April 6, 2026) found that psilocybin treatment was associated with rapid and sustained antidepressant effects that correlated with increased “brain network integration.” In simple terms, different regions of the brain appeared to communicate more flexibly after treatment. Interestingly, researchers did not observe similar brain-network changes in patients treated with the antidepressant escitalopram (Lexapro).

A randomized, placebo-controlled trial published in JAMA (Aug. 31, 2023) found that a single 25-mg dose of psilocybin, administered with careful psychological support, produced:

• Rapid improvement in depressive symptoms
• Clinically significant relief lasting at least six weeks
• Higher rates of remission than seen in many standard treatments

Participants didn’t take a daily pill. They took one supervised dose.

Editorialists in the same issue of JAMA (Aug. 31, 2023) noted the contrast with standard antidepressants, emphasizing that psychedelic therapy may help patients reframe deeply entrenched negative thinking patterns, rather than simply suppressing symptoms.

A Reader Describes Psilocybin’s Long-Lasting Effects

Q. Two of my family members have long histories of depression. Under a therapist’s supervision, each took psilocybin mushroom. We live in a state where that’s been decriminalized. That experience made a huge difference. The effects have been long-lasting for one, and the other repeated the treatment once to remarkable effect.

The therapist had seen in practice how the  psychedelics address the root cause of  depression. They seem more effective, safe, non-addicting and less costly than years of SSRIs for  many people. Also, the integration sessions  afterwards were very helpful to sort out the psychedelic experience.

I find it interesting that psychedelic plants have been used in spiritual ceremonies in almost all ancient cultures worldwide as shown by artifacts. I’m encouraged that people now seem to be more open to this possibility

Ancient Traditions and Modern Science

A. When the Spanish conquered Mexico, the friars who were spreading Christianity did all they could to suppress native spiritual and healing practices. The use of “teonanacatl,” the Nahuatl term for psilocybin mushrooms, was an important part of those practices (Journal of Antibiotics, Oct. 2020).

The Controlled Substances Act of 1970 classified psilocybin and other psychedelic compounds as Schedule I, without medical use and with a high potential for abuse. As a result, scientists had a very difficult time studying it. In recent years, though, some studies have found it helpful against depression and anxiety (Journal of
Psychopharmacology, Dec. 2016; Cochrane Database of Systematic Reviews, Sep. 12, 2024).

A recent Executive Order (April 18, 2026) calls for the FDA to “facilitate and establish a pathway for eligible patients to access psychedelic drugs…” This would presumably apply to people like your relatives as well as to research volunteers. Advocates hope this will accelerate carefully supervised research into compounds such as psilocybin, MDMA and DMT. We hope it will lead to better understanding of such compounds in the future.

Meanwhile, several states and cities have already decriminalized or loosened restrictions surrounding psilocybin use. That doesn’t necessarily mean people should rush to try it, though.

Important Warnings About Psilocybin for Depression

Researchers repeatedly emphasize that psilocybin is not a magic bullet.

In clinical studies:

• Participants are carefully screened
• Exact doses are used
• Sessions occur in highly controlled environments
• Psychological support and “integration therapy” are provided afterward

Experts caution that psychedelics can trigger anxiety, panic, paranoia or psychological distress in some people. They may be particularly risky for individuals with certain psychiatric conditions.

No one should attempt psychedelic treatment on their own!

Dimethyltryptamine or DMT in Ayahuasca:

The newest entrant in the psychedelic sweepstakes is DMT, an ultra-short-acting substance best known as a component of ayahuasca. This is a psychoactive mixture that has been used for hundreds if not thousands of years by indigenous peoples in what is now Brazil, Peru, Ecuador and Colombia.

It has a powerful history of healing. In recent years, western scientists have become interested in ayahuasca, and in particular the fast-acting hallucinogen DMT that is part of the “brew.”

New Research: DMT for Long-Lasting Depression Relief

In a study published in Nature Medicine (Feb. 16, 2026 ), researchers tested intravenous DMT in 34 people with long-lasting depression. Participants received either a 10-minute DMT infusion or a placebo infusion.

The results surprised even seasoned researchers:

• Depression scores improved more in the DMT group than in the placebo group
• The altered state of consciousness lasted about 30 minutes
• Benefits persisted for months
• DMT was “well-tolerated, with no serious adverse events”

In other words, a psychedelic experience measured in minutes produced antidepressant effects measured in months.

The authors stress caution and call for larger, longer trials, but the implication is hard to ignore: rapid, durable relief without daily medication may be possible for some people.

Why This Matters: Conventional Antidepressants Often Fall Short

Antidepressants are among the most commonly prescribed drugs in America. More than 40 million people fill hundreds of millions of prescriptions each year.

Yet their effectiveness is limited. Clinical trial data show that:

• Only about half of patients benefit
• When placebo response is factored in, antidepressants often outperform sugar pills by just 10–20%
• Side effects can include sexual dysfunction, suicidal thoughts, headaches, dizziness, dry mouth, sleep difficulties, drowsiness, nausea, etc.
• Difficult withdrawal process that can take months

Despite these limitations, antidepressants require chronic daily use, often indefinitely.

That’s the backdrop against which psychedelic research has re-emerged.

Previous Research on the Potential Benefits of Psilocybin:

Until several years ago, scientists had not conducted much research on hallucinogenic compounds. A significant stigma remained from the 1960s. However, a study from Johns Hopkins (JAMA Psychiatry, Nov. 4, 2020) confirmed that psilocybin could be helpful in treating major depression.

A British study found that it is as effective as escitalopram (Lexapro) in treating depression (New England Journal of Medicine, April 15, 2021). Moreover, a study published in Nature Medicine (April 11, 2022) explained how psilocybin from mushrooms might overcome depression.

More Research on the Magic Mushroom Ingredient for Depression:

Several years ago, two research groups published their findings that psilocybin decreased depression and anxiety in people with life-threatening cancer. (We wrote about those studies here. We also did an interview with Dr. Jeffrey Guss, one of the researchers.) Then a group of British researchers reported that psilocybin may be helpful for some people with hard-to-treat depression ( Neuropharmacology, Nov. 2018).

They used functional MRI imaging to scan the brains of 20 volunteers with resistant depression. During the scans, the subjects were shown pictures of faces with happy, fearful or neutral expressions. Then they had two sessions in which they took psilocybin under controlled conditions, with people present to provide psychological support.

Following the second session the volunteers went through another functional MRI scan. The imaging concentrated on the right amygdala, the brain structure thought to be responsible for emotional processing. Many antidepressants seem to have the effect of dampening emotions. However, psilocybin seemed to increase emotional reactions.

Individuals whose brains responded more strongly to fearful faces were more likely to report improvement in their depression in the following weeks. Thirteen of the subjects were measurably less depressed one day after the experiment finished. Nine of them were still feeling less depressed five weeks later.

The investigators concluded:

“Based on the present results, we propose that psilocybin with psychological support is a treatment approach that potentially revives emotional responsiveness in depression, enabling patients to reconnect with their emotions.”

The overall results suggest that there is still work to do. After all, fewer than half of the volunteers were able to maintain a normal mood for more than a month after the treatment. The researchers acknowledge that the next step is to conduct a randomized controlled trial. They would also like to do comparative research with SSRI-type antidepressants such as fluoxetine.

Will people suffering from major depressive disorder (MDD) be willing to consider a psychedelic substance in a controlled therapeutic setting? Will psychiatrists and other therapists be willing to contemplate such an unorthodox treatment process?

What Comes Next for Psilocybin for Depression?

Psychiatry may be entering a profoundly different era. Instead of suppressing symptoms with daily medication, psychedelic-assisted therapy may temporarily open a “window of flexibility” in the brain that allows emotional healing and psychological change.

That idea remains controversial. Larger and longer studies are still needed. Scientists are also trying to determine who is most likely to benefit and how long improvements may last. But one thing is becoming increasingly difficult to ignore: a single psychedelic experience may sometimes produce changes in mood, thinking and brain organization that persist long after the drug itself has disappeared from the body.

Important Cautions

Researchers are clear about several critical points:

• Psychedelics are not for everyone
• They were given as synthetic, precisely measured doses
• Sessions occurred with trained professionals providing psychological support
• Adverse effects—including anxiety, headache, or panic—can occur
• No one should ever attempt this on their own!

As one group of experts bluntly stated: “There are no silver bullets in psychiatry.”

Learn More:

You can learn more about psilocybin by listening to Show 1084: Psilocybin, Cancer & Spiritual Awakening. You may also find this show of interest:

Show 1188: The Healing Potential of Psychedelic Drugs
For decades, there was no research on the potential uses of psychedelic drugs. Scientists are now starting to explore how these drugs may help.

For more information about depression, you may want to read our eGuide to Dealing with Depression.

What Comes Next?

With psilocybin showing sustained benefits and DMT now demonstrating remarkably rapid effects that last several weeks, psychiatry may be entering a new chapter. This research challenges decades of assumptions about how depression must be treated. Whether regulators, clinicians, and patients are ready for that shift remains an open question.

If you have found this article of interest, please share it with family and friends by scrolling to the top of the page and clicking on the icons for email and social media. Thank you for supporting our work.